5 stories mentioning HKG:6618Updated 2d ago
Every FINWIRES story that references HKG:6618, newest first.
JD Health International (HKG:6618) has an average rating of buy and mean price target of HK$68.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
JD Health International's (HKG:6618) attributable profit rose to 3.44 billion yuan in the first half from 2.60 billion yuan in the year-ago period, according to a Thursday filing with the Hong Kong bourseEarnings per share at the pharmaceutical and healthcare products company increased to 1.07 yuan from 0.81 yuan in the prior-year period.Revenue grew 16% year over year to 40.9 billion yuan from 35.3 billion yuan.
JD Health International (HKG:6618) has an average rating of buy and mean price target of HK$75.02, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
(Corrects to remove reference to attributable profit in lead paragraph)JD Health International (HKG:6618) recorded a 78% rise in profit in the first quarter of 2026 to 1.66 billion yuan from 934.4 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The online healthcare platform's revenue for the three months jumped 17% to 19.47 billion yuan from 16.65 billion yuan in the prior-year period.The company is also planning to buy back up to $1 billion of shares from the open market over 48 months, pending approval, according to a separate stock exchange filing.
JD Health International (HKG:6618) recorded a 78% rise in attributable profit in the first quarter of 2026 to 1.66 billion yuan from 934.4 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The online healthcare platform's revenue for the three months jumped 17% to 19.5 billion yuan from 16.6 billion yuan in the prior-year period.The firm is also planning to buy back up to $1 billion of shares from the open market over 48 months, pending approval, according to a separate stock exchange filing.
